SCHEMBL6155050

SCHEMBL6155050

[CH2]C1CC(c2ccccc2)=NO1

nearest known ligand 0.54

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
ATM Q13315 1/20 0.42
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10586602 0.81 CA1 (0.53) CA1CA2
SCHEMBL27832939 0.81 MIF (0.54)
SCHEMBL27619239 0.81 LMNA (0.41) CA1CA2
SCHEMBL6156845 0.81 POLB (0.57) ATM
SCHEMBL6155053 0.76 CA1 (0.50) CA1CA2ATMPKM
SCHEMBL11982233 0.76 CA1 (0.54) CA1CA2ATMPKM
SCHEMBL10622110 0.76 CA1 (0.46) CA1CA2ATMPKM
SCHEMBL6939090 0.74 TSHR (0.51) CA1CA2ATM
SCHEMBL28653891 0.74 CA1 (0.49) CA1CA2ATMPKM
SCHEMBL28005074 0.73 CA1 (0.51) CA1CA2ATMPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6933283-B2 11-deoxy azalide antibacterials ABBOTT LABORATORIES (US) 2005-08-23 US claimed
EP-1501847-A2 11-DEOXY AZALIDE ANTIBACTERIALS Abbott Laboratories (US) 2005-02-02 EP claimed
EP-1499326-A1 OXOLIDE ANTIBACTERIALS Abbott Laboratories (US) 2005-01-26 EP claimed
US-20040014953-A1 11-Deoxy azalide antibacterials ABBVIE INC. 2004-01-22 US claimed
WO-2003090760-A1 OXOLIDE ANTIBACTERIALS ABBOTT LABORATORIES (US) 2003-11-06 WO claimed
WO-2003090679-A2 11-DEOXY AZALIDE ANTIBACTERIALS ABBOTT LABORATORIES (US) 2003-11-06 WO claimed
EP-0313997-B1 Medicine, therein contained phosphor containing 2-isoxazolidines and isoxazoles, as well as process for preparing those heterocyclic compounds HOECHST AG (DE) 1994-03-09 EP claimed
US-6933283-B2 11-deoxy azalide antibacterials ABBOTT LABORATORIES (US) 2005-08-23 US disclosed
EP-1501847-A2 11-DEOXY AZALIDE ANTIBACTERIALS Abbott Laboratories (US) 2005-02-02 EP disclosed
EP-1499326-A1 OXOLIDE ANTIBACTERIALS Abbott Laboratories (US) 2005-01-26 EP disclosed
US-20040014953-A1 11-Deoxy azalide antibacterials ABBVIE INC. 2004-01-22 US disclosed
WO-2003090679-A2 11-DEOXY AZALIDE ANTIBACTERIALS ABBOTT LABORATORIES (US) 2003-11-06 WO disclosed
WO-2003090760-A1 OXOLIDE ANTIBACTERIALS ABBOTT LABORATORIES (US) 2003-11-06 WO disclosed
EP-0313997-A2 Medicine, therein contained phosphor containing 2-isoxazolidines and isoxazoles, as well as process for preparing those heterocyclic compounds HOECHST AKTIENGESELLSCHAFT (DE) 1989-05-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014953-A1 11-Deoxy azalide antibacterials TOP1, TOP2B, TOP2A CA1 3536/4885CA2 4255/4885ATM 4431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.